What are the indications, dosing, administration routes, monitoring, and contraindications for using Kayexalate (sodium polystyrene sulfonate) in the treatment of hyperkalemia?

Kayexalate for Hyperkalemia

Kayexalate (sodium polystyrene sulfonate/SPS) should NOT be used as first-line therapy for hyperkalemia due to serious safety concerns including fatal intestinal necrosis, inconsistent efficacy, and delayed onset of action—newer potassium binders (patiromer or sodium zirconium cyclosilicate) are strongly preferred when available. 1, 2

Critical Safety Warning

The FDA label explicitly states that SPS is contraindicated in patients with obstructive bowel disease and neonates with reduced gut motility, and carries a black box-level warning for intestinal necrosis. 2 The 2021 Mayo Clinic guidelines report that SPS has been associated with:

• Fatal gastrointestinal injury including intestinal ischemia and colonic necrosis
• Doubling in risk of hospitalization for serious GI adverse events
• Overall mortality rate of 33% in reported cases 1

Concomitant administration with sorbitol is absolutely contraindicated due to increased risk of bowel necrosis. 2

Indications

SPS is FDA-approved for treatment of hyperkalemia, but with a critical limitation: it should NOT be used as emergency treatment for life-threatening hyperkalemia due to delayed onset of action (hours to days). 2

The 2021 Mayo Clinic guidelines note that clinical evidence supporting SPS use is severely limited—only one small randomized, double-blind, 7-day trial exists, and short-term efficacy is inconsistent. 1

Dosing

Oral Administration

• Standard dose: 15g orally 1-4 times daily (average total daily dose: 15-60g)
• Preparation: Suspend in 3-4 mL liquid per gram of resin (approximately 12-16 mL per 15g dose)
• One level teaspoon = 3.5g SPS = 15 mEq sodium 2

Rectal Administration

• Dose: 30-50g every 6 hours as retention enema
• Preparation: Mix in 100 mL warm aqueous vehicle, flush with 50-100 mL fluid
• Retain as long as possible, follow with cleansing enema using non-sodium containing solution 2

Administration Requirements

Critical timing: Administer at least 3 hours before or after other oral medications (6 hours in gastroparesis) due to nonselective binding that can reduce absorption of other drugs. 2 Administer with patient in upright position. 2

Prepare suspension fresh and use within 24 hours. Do not heat as this alters exchange properties. 2

Mechanism and Onset

SPS is a cation-exchange resin that binds K+ in exchange for sodium ions in the distal colon. 1 It is nonselective, also binding calcium and magnesium. 1

Onset of action is variable and slow: several hours to days, making it unsuitable for acute management. 1 The 2021 guidelines show onset ranges from "variable; several hours" compared to 7 hours for patiromer and 1 hour for SZC. 1

Monitoring

Monitor the following electrolytes closely:

• Serum potassium: Risk of hypokalemia with overcorrection
• Serum calcium: Risk of hypocalcemia due to nonselective binding
• Serum magnesium: Risk of hypomagnesemia due to nonselective binding
• Serum sodium: Each 15g dose contains 1500mg sodium—monitor for hypernatremia and volume overload 1

Monitor for gastrointestinal symptoms including constipation, diarrhea, nausea, vomiting, and abdominal pain. 1

Contraindications (Absolute)

Per FDA labeling 2:

1. Hypersensitivity to polystyrene sulfonate resins
2. Obstructive bowel disease
3. Neonates with reduced gut motility
4. Patients who have not had bowel movement post-surgery

Clinical Efficacy Data

The single randomized controlled trial showed:

• Mean K+ reduction: 1.04 mEq/L vs placebo over 7 days in outpatients with CKD and mild hyperkalemia (K+ 5.0-5.9 mEq/L)
• Dose: 30g daily for 7 days 1

Real-world data shows average K+ reduction of 0.93 mEq/L after single dose, with 10 cases of hypernatremia, 31 cases of hypokalemia, and 2 cases of bowel necrosis in 501 patients. 3

Preferred Alternatives

The 2021 Mayo Clinic guidelines and 2025 European consensus strongly recommend newer K+ binders over SPS: 1, 4

Sodium Zirconium Cyclosilicate (SZC)

• Onset: 1 hour
• Acute dosing: 10g TID for 48 hours
• Maintenance: 5-15g daily
• No serious adverse events reported in trials 1

Patiromer

• Onset: 7 hours
• Dosing: 8.4g daily, titrate to 25.2g daily
• No serious adverse events reported in trials 1

When SPS Might Be Considered

SPS may only be reasonable when:

1. Newer K+ binders are unavailable or unaffordable
2. Hyperkalemia is mild (K+ 5.0-5.5 mEq/L) and non-emergent
3. Patient has normal bowel function with recent bowel movement
4. No history of bowel disease, surgery, or constipation
5. Close monitoring is available 1, 2

Even then, the 2018 European Heart Journal consensus and 2021 Mayo guidelines suggest newer agents should be preferentially used. 5, 1

Common Pitfalls

1. Using SPS for acute/emergency hyperkalemia (K+ >6.5 mEq/L or ECG changes)—this is inappropriate due to delayed onset 2
2. Co-administering with sorbitol—absolutely contraindicated 2
3. Inadequate separation from other oral medications—leads to reduced drug absorption 2
4. Ignoring sodium load—1500mg per 15g dose can worsen heart failure or hypertension 1
5. Using in constipated patients or those with bowel dysfunction—increases necrosis risk 2